Abstract:

Objective To analyze clinical efficacy of pentoxifylline combined with edaravone-dextrocamphenol in the treatment of acute cerebral infarction. Methods From June 2021 to January 2023, 120 patients with acute cerebral infarction admitted to our hospital were collected as the research subjects. Patients were grouped into the combination group (n=60) and the single-agent group (n=60) using a random number table method. The single-agent group received intravenous infusion of edaravone-dextrocamphenol (15 mL edaravone-dextrocamphenol was injected within 0.5 h, twice a day), while the combination group received intravenous infusion of pentoxifylline based on single-agent group (0.1 g pentoxifylline was injected within 2 to 3 hours, with a maximum rate of less than 100 mg/h, twice/day). Changes of nerve function, hemodynamics and inflammatory factors before and after treatment were compared between the two groups. Results The total effective rate was significantly higher in the combination group than that of the single-agent group (95.0% vs. 81.7%, P<0.05). Compared with before treatment, the National Institutes of Health Stroke Scale (NIHSS) score, modified Rankin Scale (MRS) score, resistance index (RI), tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) were significantly decreased after treatment in both groups (P<0.05), and the combined group was more lower (P<0.05). Basel index, peak systolic flow velocity (Vs), peak diastolic flow velocity (Vd) and average blood flow velocity (Vm) were significantly increased in both groups (P<0.05), and more higher in the combined group (P<0.05). No apparent toxic reaction happened during treatment in both groups. Conclusion The combination of pentoxifylline and edaravone-dextrocamphenol has better therapeutic effect on acute cerebral infarction, which can optimize the neurological function and hemodynamics.

Key words: brain infarction, pentoxifylline, edaravone, hemodynamics, neurological function